Item type |
学術雑誌論文 / Journal Article(1) |
公開日 |
2016-04-22 |
タイトル |
|
|
タイトル |
Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice |
言語 |
|
|
言語 |
eng |
DOI |
|
|
|
関連識別子 |
https://doi.org/10.1186/s12934-015-0378-2 |
|
|
関連名称 |
10.1186/s12934-015-0378-2 |
キーワード |
|
|
主題 |
Lactococcus lactis, Heme oxygenase-1, Acute colitis, Interleukin-10, Mice, Inflammatory bowel disease |
資源タイプ |
|
|
資源 |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
著者 |
Shigemori, Suguru
Watanabe, Takafumi
Kudoh, Kai
Ihara, Masaki
Nigar, Shireen
Yamamoto, Yoshinari
Suda, Yoshihito
Sato, Takashi
Kitazawa, Haruki
Shimosato, Takeshi
|
信州大学研究者総覧へのリンク |
|
|
氏名 |
Ihara, Masaki |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.jpkaWUyV.html |
信州大学研究者総覧へのリンク |
|
|
氏名 |
Shimosato, Takeshi |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.ONLCjFkV.html |
出版者 |
|
|
出版者 |
BIOMED CENTRAL LTD |
引用 |
|
|
内容記述 |
MICROBIAL CELL FACTORIES. 14:189 (2015) |
書誌情報 |
MICROBIAL CELL FACTORIES
巻 14,
発行日 2015-11-15
|
抄録 |
|
|
内容記述 |
Background: Mucosal delivery of therapeutic proteins using genetically modified strains of lactic acid bacteria (gmLAB) is being investigated as a new therapeutic strategy. Methods: We developed a strain of gmLAB, Lactococcus lactis NZ9000 (NZ-HO), which secretes the anti-inflammatory molecule recombinant mouse heme oxygenase-1 (rmHO-1). The effects of short-term continuous oral dosing with NZ-HO were evaluated in mice with dextran sulfate sodium (DSS)-induced acute colitis as a model of inflammatory bowel diseases (IBD). Results: We identified the secretion of rmHO-1 by NZ-HO. rmHO-1 was biologically active as determined with spectroscopy. Viable NZ-HO was directly delivered to the colon via oral administration, and rmHO-1 was secreted onto the colonic mucosa in mice. Acute colitis in mice was induced by free drinking of 3 % DSS in water and was accompanied by an increase in the disease activity index score and histopathological changes. Daily oral administration of NZ-HO significantly improved these colitis-associated symptoms. In addition, NZ-HO significantly increased production of the anti-inflammatory cytokine interleukin (IL)-10 and decreased the expression of pro-inflammatory cytokines such as IL-1 alpha and IL-6 in the colon compared to a vector control strain. Conclusions: Oral administration of NZ-HO alleviates DSS-induced acute colitis in mice. Our results suggest that NZ-HO may be a useful mucosal therapeutic agent for treating IBD. |
資源タイプ(コンテンツの種類) |
|
|
内容記述 |
Article |
ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1475-2859 |
書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12039472 |
PubMed |
|
|
|
関連識別子 |
https://pubmed.ncbi.nlm.nih.gov/26608030/ |
|
|
関連名称 |
26608030 |
権利 |
|
|
権利情報 |
Copyright © Shigemori et al. 2015 |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
WoS |
|
|
URL |
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000365270300002 |